Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.
Journal Information
Full Title: Onco Targets Ther
Abbreviation: Onco Targets Ther
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure Dr Prokop Vodicka reports personal fees from Hoffmann-La Roche, outside the submitted work. Prof. Dr. Marek Trneny reports personal fees from Janssen, Gilead Sciences, BMS, Abbvie, Astra Zeneca, ROCHE Morphosys, Incyte, Novartis, and Takeda, outside the submitted work. The authors report no other conflicts of interest in this work."
"This work was supported by the Czech Health Research Council (Grant Number AZV NU21-03-00386), the project National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102; funded by the European Union – Next Generation EU), and by the Cooperation Program (research area “Oncology and Haematology”)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025